FDA BRIEF: Week of November 7, 2016fda guidances


device-reporting

For: Reporting and record-keeping requirements

  • manufacturers of medical devices
  • device-related adverse events
  • malfunctions

Scope:

  • Regulations and Basic Requirements
  • Manufacturer Reporting Requirements
  • Written Procedures, Recordkeeping and Public Disclosure
  • Specific Issues and Situations
  • Questions Concerning Completion of the MDR Report

Webinar: Nov 30th INFORMATION

READ


patient connection.JPG

CDRH Patient & Care-Partner Connection program (P&CC)

  • tied to one of CDRH’s strategic priorities to “Partner with Patients
  • build upon efforts at conducting meaningful patient engagement
  • also committed to engaging with family or care-partners who are integral to patient care and disease management

Seeking comments from interested persons FDA-2016-N-3462

General

  • Potential barriers to inclusion
  • What can FDA do to avoid or remedy
  • Appropriate and effective FDA engagement
  • Title appropriateness “Patient and Care-partner Connection”; other suggestions

Inclusion

  • Appropriate organizations for partnership
  • Barriers to effective communication between FDA, partner organizations, patients, and care-partners
  • Approaches for FDA engagement with underserved, underrepresented communities

Communication

  • Appropriate  lines of questioning
  • Positively and/or negatively viewed characteristics
  •  Preferred methods or qualities of communication

READ


ide

For: Neurological medical devices designed to slow, stop, or reverse disease progression

To: Provide general study design considerations

Overview:

  • Biological Markers and Clinical Endpoints : Biomarker Tests, Clinical Outcome Assessments
  • Trial Designs: Study Approaches and Limitations
  •  Investigational Plans
  • Safety
  • Benefit-Risk Considerations
  • Informed Consent Documents
  • Labeling : Indications for Use, Warnings and Precautions

READ


botanical

For: IND/NDA review process for botanical drug products and role of Botanical Review Team (BRT)

To: Ensure review quality and consistency

General:  BRT designated member of review team, provides pharmacognosy review, participate in submission meetings

Application Reviews: Regulatory business project managers, BRT, CMC and biopharmaceutics team members, clinical pharmacology review, nonclinical pharmacologist/toxicologist, clinical reviewers from OND and the statistical reviewers

Postapproval Activities and Surveillance

READ


 

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s